Loading stock data…
CVKD
$6.61+0.26 (+4.09%)
After Hours$6.61+0.00 (+0.00%)· Last close May 4
Cadrenal Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cadrenal Therapeutics, Inc. in the Healthcare sector is trading at $6.49. The stock is currently near its 52-week low of $4.21, remaining 32.3% below its 200-day moving average. Technical signals show overbought RSI of 72 and bullish MACD crossover, explaining why CVKD maintains its current current market pressure. The Whystock Score of 0/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 72) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.61
Potential Upside
5%
Whystock Fair Value$6.94
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$27.67+318.6%
Range$13.00 – $45.00
Fundamentals
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart att...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$14.69M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.55
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-483.34%
Volume
Today's trading volume
56,472
Recent News
Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program
We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Cadrenal Therapeutics, Inc. is among the oversold biotech stocks to invest in now. TheFly reported on April 7 that H.C. Wainwright reduced its price target on CVKD from $32 to $13 while maintaining a Buy rating. The adjustment reflects updated […]
Cadrenal Therapeutics, Inc.
CVKD: Acquires Factor XIa Inhibitors
Cadrenal Therapeutics acquires eXIthera’s Factor XIa inhibitors
Cadrenal will acquire eXIthera’s intravenous Factor XIa inhibitor frunexian, oral inhibitor EP-7327, and additional novel FXIa small molecules.